NewcelX Ltd

@newcelXltd prices $1.35M equity financing at a 30% premium, with participation from existing shareholders, strengthening execution of NCEL-101 for Type 1 Diabetes. #Biotech #CellTherapy #Type1Diabetes #NASDAQ finance.yahoo.com/sectors/health…

@newcelXltd (Nasdaq: NCEL) announces collaboration with @Eledon_Pharma (Nasdaq: ELDN) to advance NCEL-101 for Type 1 Diabetes. ✔ Stem-cell-derived islet replacement ✔ Immune-modulation under @FDA_Drug_Info -cleared IND applications ✔ Built on experience from 100+ procedures

$NCEL reports peer-reviewed publication supporting Mazindol ER in Clinical Drug Investigation. ✔️ Third-party scientific validation ✔️ Strengthened positioning in active licensing & acquisition discussions ✔️ CVR monetization strategy advancing DOI: doi.org/10.1007/s40261…

🔬 $NCEL Update: We’ve released our latest Corporate Presentation ahead of the Spring 2026 investor circuit! ✅ Focus on #T1D cell therapy ✅ Introducing our Scientific Advisory Board ✅ Ready for Investor and Partnering Conferences Check out our website #BiotechNews #StemCells

NewcelX shared positive results from an international study exploring biomaterial-based delivery of stem cell–derived islets for Type 1 Diabetes The findings support safer, retrievable approaches to insulin-producing cell therapies — a key focus of our IsletRx program.

Grateful to our shareholders and partners as we move forward as NewCelX Ltd. (Nasdaq: NCEL). Clear focus on #type1diabetes, strengthened leadership, and key clinical momentum across our pipeline. Full statement from our Exec. Chairman and CEO @RonenTwito: linkedin.com/posts/newcelx_…

@newcelXltd welcomes Dr. @julienboisdron , to our Scientific Advisory Board. With years of global #diabetes #leadership in Swiss #BigPharma , Dr. Boisdron will help guide IsletRx, our lead program and core company focus in Type 1 Diabetes, as we move toward clinical development.

Season’s greetings from all of us at NewcelX 🎄 Thank you for being part of our journey. Wishing you a Merry #Christmas and a wonderful New Year. #NewYear #HappyHolidays

Source: @WVVA by Heather Olinger: wvva.com/2025/12/23/don…

Holiday routines can disrupt #diabetes management — consistent meals, balanced plates, and short walks help keep glucose steady. At NewCelX, our IsletRx stem cell program aims to advance new therapies to help people with insulin-dependent diabetes.

NewcelX expands its global IP footprint: Our DOXA patent application has been published in #China 🇨🇳 — strengthening our small-molecule platform across #Neurology, #sleep-wake disorders, and metabolic disease. Another key step in advancing next-generation CNS innovation.

Big moment for #NewcelX! 🌟 Our logo and video lit up the @Nasdaq Tower in Times Square, celebrating our debut as a Nasdaq-listed biotech company focused on cell therapy, regenerative medicine, and neuroscience innovation. #Nasdaq #Biotech #Innovation

We’re honored to welcome Prof. Jeremy Shefner, MD, PhD, Chief Medical Officer at @BarrowNeuro Institute, to the NewcelX Scientific Advisory Board. His expertise in ALS and neurodegenerative diseases will help drive our mission to deliver transformative therapies.